Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients.
OBJECTIVE
To evaluate the effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients.


METHODS
A randomized, double-blind, placebo-controlled clinical trial was carried out in 12 obese, dyslipidaemic patients, independently of their basal insulin sensitivity. At the beginning of the study, a metabolic profile was measured, and insulin sensitivity estimated using the euglycaemic-hyperinsulinaemic clamp technique. The volunteers were randomly assigned to receive ezetimibe (10 mg/day in the morning) or placebo for a period of 90 days. After intervention, a similar metabolic profile was measured and a second clamp study was performed.


RESULTS
Ezetimibe administration for 90 days decreased total (6.0 +/- 0.5 vs. 4.2 +/- 0.9 mmol/L, p = 0.011) and low-density lipoprotein (4.0 +/- 0.7 vs. 2.2 +/- 0.8 mmol/L, p=0.003) cholesterol concentrations without modification of insulin sensitivity (3.0 +/- 0.6 vs. 2.9 +/- 0.7 mg/kg/min, p = 0.345).


CONCLUSIONS
Ezetimibe significantly decreased total cholesterol and low-density lipoprotein cholesterol concentrations without affecting insulin sensitivity in obese and dyslipidaemic patients.
González-Ortiz
Manuel
M
Medical Research Unit in Clinical Epidemiology, Specialties Hospital, West National Medical Center, Mexican Institute of Social Security, Belisario Domínguez, Colonia Independencia, Guadalajara, Jalisco. uiec@prodigy.net.mx
Martínez-Abundis
Esperanza
E
Kam-Ramos
Angélica María
AM
Hernández-Salazar
Eduardo
E
Ramos-Zavala
Maria Guadalupe
MG
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001384:Azetidines / Q000008:administration & dosage / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D001795:Blood Pressure Determination; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004311:Double-Blind Method; D050171:Dyslipidemias / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D001384:Azetidines; D001786:Blood Glucose; D008078:Cholesterol, LDL; D008055:Lipids; D002784:Cholesterol; D000069438:Ezetimibe